Psoriatic Arthritis — RepurpOS

Disease overview

Alterations

155

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

134

Natural agents

Natural products

Merged ranked

211

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Examine.com, PubMed NP Literature · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Spontaneous remission uncommon (<5%); progressive joint damage in 40-60% without adequate treatment; enthesitis, dactylitis, axial involvement accumulate over time

Best-intervention remission

IL-17 inhibitors: ACR50 response 58-62%, MDA (minimal disease activity) in 40-50%; IL-23 inhibitors (guselkumab, risankizumab): similar efficacy with better skin clearance; JAK inhibitors (upadacitinib): ACR50 71% at 26 weeks; drug-free remission in ~15% in early PsA with T2T

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — most patients are undertreated on methotrexate or NSAIDs alone; treat-to-target poorly implemented

Primary barrier

practice/access

Barrier detail: Diagnostic delay (mean 5-7 years from symptom onset to PsA diagnosis); methotrexate has modest efficacy in PsA but is gatekept as mandatory step before biologic access in many health systems; treat-to-target (MDA as goal) poorly implemented; most patients cycle through multiple NSAIDs before biologic access

Last SoC change: 2023 — upadacitinib first-line biologic approved for PsA; deucravacitinib (TYK2) Phase 3 data; 2020 guselkumab/risankizumab for PsA; tofacitinib/ixekizumab since 2017-2018; anti-TNF standard since 2003

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0011849 · ORPHA: ORPHA:163927

Right to Try Relevance

Eligibility: This disease meets the federal and state right-to-try legal standard (21 U.S.C. § 360bbb-0a and Montana SB 535): it lacks disease-modifying therapy with indication-specific FDA approval. Patients with Psoriatic Arthritis may be eligible to access investigational therapies outside of clinical trials under right-to-try frameworks.

Investigational Agents

Phase 3: 17, Phase 2: 18, Phase 1: 5

Most Advanced Phase

Phase 3

Highest dev. stage

Gene Targets

155

Actionable

Pipeline Compounds (Top 6)

Betamethasone, Bimekizumab, Calcipotriene, Deucravacitinib, Filgotinib, Icotrokinra

Legal Standard: Right-to-try requires the disease lacks "adequate approved therapy for that specific disease" (not symptom-management drugs). This distinction means a disease with antidepressants available still qualifies if no FDA approval exists for THAT disease indication.

View Right-to-Try Compendium

Alterations

Showing 80 of 155 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Abnormal shoulder morphology	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of the knee	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of the temporomandibular joint	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of the wrist	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Abnormality of tumor necrosis factor secretion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Anterior uveitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Antinuclear antibody positivity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Arthralgia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Arthritis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Autoimmunity	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Enthesitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Finger dactylitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Generalized morning stiffness	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Iridocyclitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Iritis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Limitation of joint mobility	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Malar rash	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Nail pits	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Oligoarthritis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Onycholysis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Polyarticular arthritis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Pruritus	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Psoriasiform dermatitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Psoriasiform lesion	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Reduced visual acuity	Lab / Clinical	Lab value	—	—	Moderate	HPO, Monarch	HPO
Sacroiliac arthritis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Skin rash	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Toe dactylitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Uveitis	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ADARB2 adenosine deaminase RNA specific B2 (inactive)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AKT3 AKT serine/threonine kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ALDH1A1 aldehyde dehydrogenase 1 family member A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ANKRD55 ankyrin repeat domain 55	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ANO5 anoctamin 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Adverse Events (AEs)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
C1orf141 chromosome 1 open reading frame 141	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C1orf21 chromosome 1 open reading frame 21	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD226 CD226 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD80 CD80 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD86 CD86 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDH12 cadherin 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHSY3 chondroitin sulfate synthase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CNOT4 CCR4-NOT transcription complex subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COL15A1 collagen type XV alpha 1 chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COL25A1 collagen type XXV alpha 1 chain	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CRPPA CDP-L-ribitol pyrophosphorylase A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSMD1 CUB and Sushi multiple domains 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change From Baseline in DAS28 (ESR)	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in WPAI Scores (Percent Impairment While Working) at Weeks 24 and 52	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in WPAI Scores (Percent Work Time Missed) at Weeks 52, 76 and 100	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Work Productivity and Activity Impairment Scores (Percent Work Time Missed) at Weeks 16 and 24	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DENND3 DENN domain containing 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DHFR dihydrofolate reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DHODH dihydroorotate dehydrogenase (quinone)	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DMPK DM1 protein kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ELANE elastase, neutrophil expressed	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EPHA4 EPH receptor A4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERAP2 endoplasmic reticulum aminopeptidase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ERG ETS transcription factor ERG	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ETV1 ETS variant transcription factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAM8A1 family with sequence similarity 8 member A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAS Fas cell surface death receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXO11 F-box protein 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FLRT2 fibronectin leucine rich transmembrane protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FRMD3 FERM domain containing 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FTO FTO alpha-ketoglutarate dependent dioxygenase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GIPR gastric inhibitory polypeptide receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLP1R glucagon like peptide 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GNG4 G protein subunit gamma 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPR55 G protein-coupled receptor 55	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HDGFL1 HDGF like 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Health Assessment Questionnaire	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
IFIH1 interferon induced with helicase C domain 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

FDA-Approved Therapies

Phase 4 agents with regulatory approval for this indication

Drug Name	Mechanism	Type
5-HYDROXYTRYPTOPHAN		Gene-targeted
ABATACEPT	inhibitor	Gene-targeted
ACETAZOLAMIDE	None	Gene-targeted
AMITRIPTYLINE HYDROCHLORIDE		Gene-targeted
AMPHETAMINE	None	Gene-targeted
ANTI-THYMOCYTE GLOBULIN		Gene-targeted
APIGENIN		Gene-targeted
AZACITIDINE		Gene-targeted
BELATACEPT	inhibitor	Gene-targeted
BICALUTAMIDE	None	Gene-targeted
BIFONAZOLE		Gene-targeted
BITHIONOL		Gene-targeted
BRIMONIDINE		Gene-targeted
BUSPIRONE		Gene-targeted
BUSPIRONE HYDROCHLORIDE		Gene-targeted
CAMPHOR OIL		Gene-targeted
CAPIVASERTIB		Gene-targeted
CAPSAICIN		Gene-targeted
CARBACHOL	None	Gene-targeted
CARBIDOPA ANHYDROUS		Gene-targeted
CARBOPLATIN		Gene-targeted
CARMUSTINE		Gene-targeted
CHLORAMPHENICOL		Gene-targeted
CILOSTAZOL		Gene-targeted
CIPROFLOXACIN	None	Gene-targeted
CISPLATIN		Gene-targeted
CITRATE		Gene-targeted
CLIOQUINOL		Gene-targeted
CLOMIPRAMINE	None	Gene-targeted
CLOPIDOGREL		Gene-targeted
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM	cleavage	Gene-targeted
CYCLOSPORINE		Gene-targeted
DEXAMETHASONE		Gene-targeted
DIAZEPAM	None	Gene-targeted
DICHLORPHENAMIDE	None	Gene-targeted
DICUMAROL		Gene-targeted
DIETHYLSTILBESTROL	None	Gene-targeted
DIMERCAPROL		Gene-targeted
DISULFIRAM		Gene-targeted
DOCONEXENT		Gene-targeted

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
5-HYDROXYTRYPTOPHAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABATACEPT Repurposing	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 10 Meta-analysis 7 Trial pubs 6 RCT View evidence Registry trials NCT01965132 — Korean College of Rheumatology Biologics and Targeted Therapy Registry (RECRUITING) NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2 NCT03496831 — Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs (COMPLETED) NCT05421442 — A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database (COMPLETED) NCT03419143 — Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants (COMPLETED) NCT01860976 — Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (COMPLETED) PHASE3 NCT04106804 — Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker (UNKNOWN) PHASE4 NCT05080218 — COVID-19 VaccinE Response in Rheumatology Patients (COMPLETED) PHASE4 Published literature Cochrane review Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review (Autoimmunity reviews, 2023) Cochrane review Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis (Pharmaceutics, 2022) Cochrane review Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis (Annals of the rheumatic diseases, 2020) Cochrane review Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review (Expert review of clinical pharmacology, 2020) Cochrane review Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes (Clinical and experimental rheumatology, 2020) Systematic review Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review (BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2021) Clinical trial publication Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis (Rheumatology (Oxford, England), 2022) Clinical trial publication Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis (Rheumatology international, 2020) Clinical trial publication Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial (Arthritis research & therapy, 2018) Clinical trial publication Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis (Arthritis research & therapy, 2017) Clinical trial publication Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Annals of the rheumatic diseases, 2017) Randomized controlled trial Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial (The Journal of rheumatology, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANTI-THYMOCYTE GLOBULIN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
APIGENIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BELATACEPT Repurposing	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BUSPIRONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSPIRONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CAMPHOR OIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPIVASERTIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPSAICIN Repurposing	Small molecule	Approved	Strong	95	1 Cochrane View evidence Published literature Cochrane review Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review (The Journal of rheumatology. Supplement, 2012) CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBIDOPA ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORAMPHENICOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CILOSTAZOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CLIOQUINOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOPIDOGREL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOSPORINE Repurposing	Small molecule	Approved	Strong	95	3 trials 2 Cochrane 1 Meta-analysis 3 Trial pubs 1 RCT View evidence Registry trials NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2 NCT01706692 — Swiss Dermatology Network of Targeted Therapies (SDNTT) (RECRUITING) NCT01848028 — PsoBest - The German Psoriasis Registry (RECRUITING) Published literature Cochrane review Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (The Journal of rheumatology, 2023) Cochrane review A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis (Annals of the rheumatic diseases, 2012) Systematic review Emerging biological therapies for psoriatic arthritis: A systematic review (Medicine, 2025) Systematic review Systematic Review and Recommendations to Combine Newer Therapies With Conventional Therapy in Psoriatic Disease (Frontiers in medicine, 2021) Systematic review Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review (The Journal of dermatological treatment, 2022) Systematic review Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies (Cutis, 2018) Clinical trial publication Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial (The Journal of rheumatology, 2011) Clinical trial publication Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study (American journal of clinical dermatology, 2009) Clinical trial publication A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis (The Journal of rheumatology, 2001) CT.gov search · Cochrane · PubMed	DGIdb	—
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases (RECRUITING) CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICUMAROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIMERCAPROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOCONEXENT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DOXEPIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DYCLONINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DYCLONINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EDARAVONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPHEDRINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ETHACRYNIC ACID Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EUGENOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EVEROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Sources	Links
BETAMETHASONE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BIMEKIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CALCIPOTRIENE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DEUCRAVACITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
FILGOTINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ICOTROKINRA	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
IVARMACITINIB SULFATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
M-1095	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
NETAKIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
SIVELESTAT	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TALAZOPARIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TILDRAKIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
TOFACITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VANADATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
VUNAKIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ZASOCITINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ALEFACEPT	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BREPOCITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CENACITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CLAZAKIZUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DIMETHYL FUMARATE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DRONABINOL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
IZOKIBEP	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LUTIKIZUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
NABIXIMOLS	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
NEIHULIZUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
PICANKIBART	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
REMTOLUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TEPLIZUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TULISOKIBART	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ZUNSEMETINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BELUMOSUDIL	Small molecule	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets
EFALIZUMAB	Biologic	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets
GSK-3050002	Small molecule	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets
NIVOLUMAB	Biologic	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets
PERAKIZUMAB	Biologic	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
5-HYDROXYTRYPTOPHAN Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
ABATACEPT Repurposing via CD80	Small molecule	Approved	Strong	95	8 trials 8 Cochrane 10 Meta-analysis 7 Trial pubs 6 RCT View evidence Registry trials NCT01965132 — Korean College of Rheumatology Biologics and Targeted Therapy Registry (RECRUITING) NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2 NCT03496831 — Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs (COMPLETED) NCT05421442 — A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database (COMPLETED) NCT03419143 — Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants (COMPLETED) NCT01860976 — Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (COMPLETED) PHASE3 NCT04106804 — Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker (UNKNOWN) PHASE4 NCT05080218 — COVID-19 VaccinE Response in Rheumatology Patients (COMPLETED) PHASE4 Published literature Cochrane review Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review (Autoimmunity reviews, 2023) Cochrane review Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis (Pharmaceutics, 2022) Cochrane review Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis (Annals of the rheumatic diseases, 2020) Cochrane review Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review (Expert review of clinical pharmacology, 2020) Cochrane review Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes (Clinical and experimental rheumatology, 2020) Systematic review Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review (BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2021) Clinical trial publication Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis (Rheumatology (Oxford, England), 2022) Clinical trial publication Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis (Rheumatology international, 2020) Clinical trial publication Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial (Arthritis research & therapy, 2018) Clinical trial publication Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis (Arthritis research & therapy, 2017) Clinical trial publication Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Annals of the rheumatic diseases, 2017) Randomized controlled trial Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial (The Journal of rheumatology, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
ACETAZOLAMIDE Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
AMITRIPTYLINE HYDROCHLORIDE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANTI-THYMOCYTE GLOBULIN Repurposing via CD86	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
APIGENIN Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BELATACEPT Repurposing via CD80	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BICALUTAMIDE Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
BUSPIRONE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
BUSPIRONE HYDROCHLORIDE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
CAMPHOR OIL Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPIVASERTIB Repurposing via AKT3	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPSAICIN Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	1 Cochrane View evidence Published literature Cochrane review Efficacy and safety of neuromodulators in inflammatory arthritis: a Cochrane systematic review (The Journal of rheumatology. Supplement, 2012) CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARBIDOPA ANHYDROUS Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBOPLATIN Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CARMUSTINE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CHLORAMPHENICOL Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CILOSTAZOL Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CIPROFLOXACIN Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CISPLATIN Repurposing via CD80	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CITRATE Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CLIOQUINOL Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CLOMIPRAMINE Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOPIDOGREL Repurposing via CD80	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM Repurposing via COL15A1	Small molecule	Approved	Strong	95	—	DGIdb	—
CYCLOSPORINE Repurposing via CD80	Small molecule	Approved	Strong	95	3 trials 2 Cochrane 1 Meta-analysis 3 Trial pubs 1 RCT View evidence Registry trials NCT07138898 — Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (NOT_YET_RECRUITING) PHASE2 NCT01706692 — Swiss Dermatology Network of Targeted Therapies (SDNTT) (RECRUITING) NCT01848028 — PsoBest - The German Psoriasis Registry (RECRUITING) Published literature Cochrane review Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (The Journal of rheumatology, 2023) Cochrane review A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis (Annals of the rheumatic diseases, 2012) Systematic review Emerging biological therapies for psoriatic arthritis: A systematic review (Medicine, 2025) Systematic review Systematic Review and Recommendations to Combine Newer Therapies With Conventional Therapy in Psoriatic Disease (Frontiers in medicine, 2021) Systematic review Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review (The Journal of dermatological treatment, 2022) Systematic review Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies (Cutis, 2018) Clinical trial publication Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial (The Journal of rheumatology, 2011) Clinical trial publication Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study (American journal of clinical dermatology, 2009) Clinical trial publication A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis (The Journal of rheumatology, 2001) CT.gov search · Cochrane · PubMed	DGIdb	—
DEXAMETHASONE Repurposing via CD86	Small molecule	Approved	Strong	95	1 trials View evidence Registry trials NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases (RECRUITING) CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICUMAROL Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
DIETHYLSTILBESTROL Repurposing via AKT3	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIMERCAPROL Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
DISULFIRAM Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—
DOCONEXENT Repurposing via ALDH1A1	Small molecule	Approved	Strong	95	—	DGIdb	—

Natural Products

15 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

Show agents without direct trial evidence

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Omega-3 Fatty Acids Natural product Randomized controlled trial Nutritional effect on lipoproteins and their subfractions in patients w… Human Study Seal oil rich in the essential fatty acid EPA results in subjective imp…	Nutraceutical	Preclinical	Moderate	20	1 RCT View evidence Published literature Randomized controlled trial Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial (Advances in rheumatology (London, England), 2024) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin D3 Natural product Human Study Vitamin D generates significant improvement in psoriatic arthritis.	Nutraceutical	Phase II	Moderate	20	2 trials View evidence Registry trials NCT02854163 — Effect of Secukinumab in the Treatment of Psoriatic Arthritis (COMPLETED) PHASE2 NCT04892602 — Fibromyalgia in Rheumatiod and Psoriatic Patients (COMPLETED) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin E Natural product Human Study Vitamin D generates significant improvement in psoriatic arthritis.	Nutraceutical	Preclinical	Moderate	20	1 Meta-analysis View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Coenzyme Q10 Natural product	Nutraceutical	Preclinical	Moderate	17	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Curcumin Natural product Cochrane review Efficacy of Spice Supplementation in Rheumatoid Arthritis: A Systematic…	Food compound	Preclinical	Moderate	17	1 Cochrane View evidence Published literature Cochrane review Efficacy of Spice Supplementation in Rheumatoid Arthritis: A Systematic Literature Review (Nutrients, 2020) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin D3 Natural product Human Study Vitamin D generates significant improvement in psoriatic arthritis.	Nutraceutical	Phase II	Emerging	16	2 trials View evidence Registry trials NCT02854163 — Effect of Secukinumab in the Treatment of Psoriatic Arthritis (COMPLETED) PHASE2 NCT04892602 — Fibromyalgia in Rheumatiod and Psoriatic Patients (COMPLETED) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Omega-3 Fatty Acids Natural product Randomized controlled trial Nutritional effect on lipoproteins and their subfractions in patients w… Human Study Seal oil rich in the essential fatty acid EPA results in subjective imp…	Nutraceutical	Preclinical	Emerging	10	1 RCT View evidence Published literature Randomized controlled trial Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial (Advances in rheumatology (London, England), 2024) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Vitamin E Natural product Human Study Vitamin D generates significant improvement in psoriatic arthritis.	Nutraceutical	Preclinical	Emerging	10	1 Meta-analysis View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Thunder God Vine Natural product	Nutraceutical	Preclinical	Moderate	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	Examine.com
Coenzyme Q10 Natural product Oxidative Imbalance in Psoriasis with an Emphasis on Psoriatic Arthriti…	Nutraceutical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Curcumin Natural product Cochrane review Efficacy of Spice Supplementation in Rheumatoid Arthritis: A Systematic…	Food compound	Preclinical	Emerging	7	1 Cochrane View evidence Published literature Cochrane review Efficacy of Spice Supplementation in Rheumatoid Arthritis: A Systematic Literature Review (Nutrients, 2020) CT.gov search · Cochrane · PubMed	Examine.com	PubChem Examine.com
Probiotics Natural product Systematic review Dietary recommendations of the French Society for Rheumatology for pati… Systematic review Characterization of the Oral and Gut Microbiota in Patients with Psoria… Clinical trial publication Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therape…	Probiotic	Preclinical	Emerging	7	1 trials 3 Cochrane 1 Meta-analysis 1 Trial pubs View evidence Registry trials NCT04588623 — The MEDIPSA Clinical Trial (COMPLETED) NA Published literature Systematic review Dietary recommendations of the French Society for Rheumatology for patients with chronic inflammatory rheumatic diseases (Joint bone spine, 2022) Systematic review Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review (Acta dermato-venereologica, 2021) Clinical trial publication Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches (International journal of molecular sciences, 2023) CT.gov search · Cochrane · PubMed		—
Sea Salt: Dead Sea Natural product Human Study Balneotherapy at the Dead Sea area appears to produce a statistically s… Human Study Balneotherapy, sunlight exposure and mud therapy at the Dead Sea have t… Human Study Dead sea salt has therapeutic value in the treatment of psoriatic arthr…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed		—
Seal Oil Natural product Clinical trial publication Subjective improvement in patients with psoriatic arthritis after short…	Nutraceutical	Preclinical	Emerging	0	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil (The Journal of rheumatology, 2006) CT.gov search · Cochrane · PubMed		—
Delphinidin Natural product Animal Study, In Vitro Study Delphinidin diminishes in vitro interferon-γ and interleukin-17 produci…	Nutraceutical	Preclinical	Emerging	0	1 pubs View evidence CT.gov search · Cochrane · PubMed		—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.